spiro[3.4]oct-5-en-6-yl-methanol | 1147732-87-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: spiro[3.4]oct-5-en-6-yl-methanol
• 英文别名: Spiro[3.4]oct-7-en-7-ylmethanol
• CAS: 1147732-87-3
• 化学式: C₉H₁₄O
• 分子量: 138.21
• InChiKey: PGMDMPYJYHGXKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF
  申请人：Shimada Takashi

  公开号：US20090170908A1

  公开（公告）日：2009-07-02

  The Spiro compound represented by the following general formula [Ia], its pharmaceutically acceptable salt or a solvate thereof

  以下是用中文翻译的结果：由下列通用式[Ia]表示的螺环化合物，其药用可接受盐或其溶剂化合物
• NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE
  申请人：OHKOUCHI Munetaka

  公开号：US20120277150A1

  公开（公告）日：2012-11-01

  [Object] To provide a GPR40 activating agent containing, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the compound or the salt, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of Solving the Problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 2; k is 0 to 1; a ring A is an aryl group, a heterocyclic group, a cycroalkyl group, a cycroalkenyl group, a spirocyclic group; a ring B is an aryl group, a heteroaryl group; X is 0 or —NR 7 —; and R 1 to R 7 and L are specific groups), a salt of the compound, or a solvate of the compound or the salt.

  提供一种包含GPR40激活剂的药剂，其活性成分为具有GPR40激动剂作用的新化合物、该化合物的盐、该化合物或盐的溶剂化合物等，特别是胰岛素促分泌剂和预防和/或治疗糖尿病、肥胖或其他疾病的药物。解决问题的方法是使用式(I)的化合物：（其中p为0至4；j为0至2；k为0至1；环A为芳基、杂环基、环烷基、环烯基、螺环基；环B为芳基、杂芳基；X为0或-NR7-；R1至R7和L为特定基团），该化合物的盐或该化合物或盐的溶剂化合物。
• CYCLIC AMIDE DERIVATIVE
  申请人：Okano Akihiro

  公开号：US20140057871A1

  公开（公告）日：2014-02-27

  [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogues and a prophylactic and/or therapeutic agent against diabetes, obesity, or the like. [Means of solving the problem] A compound of Formula (III): (where f is 0 to 2; g is 1 to 4; j is 0 to 3; k is 0 to 2; n is 0 to 2; p is 0 to 4; h is 0 to 3; q1 id 0 to 3; q2 is 0 or 1; r1 is 0 to 2 (with the proviso that q1+q2+r1 is 0 to 5); J 1a is —CR 11a —, N; J 2 is —CR 12a R 12b —, —CR 12c —; T is —CH 2 —, O, —S(O) i — (i is an integer of 0 to 2) or —NR 7 —; X is O, S, or —NR 7 —; ring A′″ is a benzene ring, a pyridine ring; ring B′ is a benzene ring, a pyridine ring, a pyrimidine ring; and R 1 to R 14 are specific groups), a salt of the compound, or a solvate of the salt or the compound.

  [问题]提供一种GPR40激活剂，其活性成分为具有GPR40激动剂作用的新化合物、该化合物的盐、盐或化合物的溶剂化物等，特别是胰岛素分泌剂和预防和/或治疗糖尿病、肥胖症等的药物。[解决问题的方法]化合物的式子为(III):(其中f为0到2；g为1到4；j为0到3；k为0到2；n为0到2；p为0到4；h为0到3；q1为0到3；q2为0或1；r1为0到2(条件是q1 + q2 + r1为0到5)；J1a是—CR11a—，N；J2是—CR12aR12b—，—CR12c—；T是—CH2—、O、—S(O)i—(i为0到2的整数)或—NR7—；X是O、S或—NR7—；环A'″是苯环、吡啶环；环B'是苯环、吡啶环、嘧啶环；R1到R14是特定的基团），该化合物的盐或盐或化合物的溶剂化物。
• NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：US20130210721A1

  公开（公告）日：2013-08-15

  [Object] To provide a GPR40 activating agent containing, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the compound or the salt, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of Solving the Problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 2; k is 0 to 1; a ring A is an aryl group, a heterocyclic group, a cycroalkyl group, a cycroalkenyl group, a spirocyclic group; a ring B is an aryl group, a heteroaryl group; X is O or —NR 7 —; and R 1 to R 7 and L are specific groups), a salt of the compound, or a solvate of the compound or the salt.

  [目的] 提供一种GPR40激活剂，其中包含一种具有GPR40激动剂作用的新化合物作为活性成分，该化合物的盐、化合物或盐的溶剂合物等，特别是胰岛素分泌剂和预防和/或治疗糖尿病、肥胖症或其他疾病的药物。 [解决问题的方法] 公式(I)的化合物： 其中p为0至4；j为0至2；k为0至1；环A为芳基、杂环基、环烷基、环烯基、螺环基；环B为芳基、杂芳基；X为O或-NR7-；R1至R7和L为特定的基团，该化合物的盐或化合物或盐的溶剂合物。
• SPIRO-RING COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES
  申请人：Japan Tobacco Inc.

  公开号：EP2202216A1

  公开（公告）日：2010-06-30

  The spiro compound represented by the following general formula [Ia], its pharmaceutically acceptable salt or a solvate thereof

  以下通式[Ia]代表的螺环化合物、其药学上可接受的盐或其溶液